The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Diabetic Nephropathy
- Registration Number
- NCT00044148
- Lead Sponsor
- Chromaderm, Inc.
- Brief Summary
The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety of LY333531 and any side effects that may be associated with it.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Type 2 diabetes mellitus
- Greater than or equal to 30 years of age
- Albumin to Creatinine ratio (greater than 200 mg/g and less than 2000 mg/g) 4)Without language barrier.
Exclusion Criteria
- Serum Creatinine greater than 2.0 mg/dl males or greater than 1.7 mg/dl females
- B/P greater than 150 systolic and greater than 90 diastolic
- Hemoglobin Alc greater than 11%
- Liver Function Tests 2 times upper limit of normal
- Poor medical or psychiatric risk.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method